Published in

BMJ Publishing Group, Regional Anesthesia & Pain Medicine, 9(45), p. 677-678, 2020

DOI: 10.1136/rapm-2020-101584

Links

Tools

Export citation

Search in Google Scholar

NSAIDs for analgesia in the era of COVID-19

Journal article published in 2020 by Daniel L. Herzberg ORCID, Harry P. Sukumaran, Eugene Viscusi ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Globally, non-steroidal anti-inflammatory drugs (NSAIDs) are highly used to treat pain. With the rise of the COVID-19 pandemic, the safety of NSAIDs use has been called into question. These concerns are worthy of review. At present, there is no compelling data showing that NSAIDs worsen the severity of COVID-19 symptoms or increase one’s likelihood of contracting the illness. For patients in pain and without symptoms that could potentially be attributed to COVID-19 (cough, fevers/chills, lethargy, myalgias, anosmia and so on), NSAIDs should continue to remain a viable option to provide analgesia to patients in need.